Premium
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
Author(s) -
Reading Paul J.,
Luce Anna K,
McKeith Ian G.
Publication year - 2001
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.1204
Subject(s) - rivastigmine , psychosis , psychiatry , parkinson's disease , cognition , psychology , medicine , open label , distress , schizophrenia (object oriented programming) , cognitive impairment , randomized controlled trial , dementia , disease , clinical psychology , donepezil
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug. © 2001 Movement Disorder Society.